Pedro Perez: “Provoked” VTE May Not Always Mean the Risk Disappears When the Provoking Event Does
Pedro Perez, Southeast Vascular Sales Manager at Argon Medical Devices, Inc., shared a post on LinkedIn about a recent article Andrew Peseski et al., published in Blood Advances, adding:
“‘Provoked’ VTE may not always mean the risk disappears when the provoking event does.
A timely September 2026 commentary in Blood Advances highlights results from the HI-PRO trial, which examined patients with a provoked VTE who also had persistent risk factors.
Extended thromboprophylaxis was associated with lower recurrent VTE, challenging the traditional assumption that every provoked DVT or PE should automatically follow the same time-limited anticoagulation strategy.
This aligns with a broader shift in VTE care: treatment duration is becoming increasingly individualized around recurrence risk versus bleeding risk, rather than simply labeling an event ‘provoked’ or ‘unprovoked.’
The 2026 American College of Cardiology scientific statement on DOACs similarly emphasizes contemporary evidence for individualized thromboembolic management.
The question may no longer be just ‘What caused the clot?’ but also ‘What risk remains after the initial cause is gone?’
Could better identification of persistent risk factors change how we define—and treat—provoked VTE?”
Title: The complexity of “provoked” venous thromboembolism: one treatment plan does not fit all Commentary on the HI-PRO Trial.
Authors: Andrew Peseski, Sargam Kapoor, Thomas L. Ortel
Other posts featuring Pedro Perez on Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian